U.S. Markets close in 2 hrs 17 mins

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
5.35-0.32 (-5.64%)
As of 1:40PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close5.67
Open5.56
Bid5.35 x 1100
Ask5.41 x 1000
Day's Range5.26 - 5.59
52 Week Range2.23 - 10.71
Volume146,884
Avg. Volume417,104
Market Cap138.074M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales
    Business Wire

    AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales

    AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma.

  • Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
    Zacks

    Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

    Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

  • AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
    Zacks

    AnaptysBio Shares Up on Positive Top-Line Psoriasis Data

    AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.